Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
May 08, 2024 16:05 ET
|
Sana Biotechnology, Inc
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell...
Sana Biotechnology to Present at May and June 2024 Investor Conferences
May 06, 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 29, 2024 16:05 ET
|
Sana Biotechnology, Inc
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in...
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
February 28, 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
February 13, 2024 16:05 ET
|
Sana Biotechnology, Inc
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence...
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 12, 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
Sana Biotechnology Announces Pricing of Upsized Public Offering
February 08, 2024 01:22 ET
|
Sana Biotechnology, Inc
SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
Sana Biotechnology Announces Proposed Public Offering of Common Stock
February 07, 2024 16:01 ET
|
Sana Biotechnology, Inc
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
January 05, 2024 09:00 ET
|
Sana Biotechnology, Inc
SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food...
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...